Plasma Circulating Mirnas Profiling for Identification of Potential Breast Cancer Early Detection Biomarkers
- PMID: 34048164
- PMCID: PMC8408402
- DOI: 10.31557/APJCP.2021.22.5.1375
Plasma Circulating Mirnas Profiling for Identification of Potential Breast Cancer Early Detection Biomarkers
Abstract
Objective: This study aimed to characterize the miRNA expression profiles from plasma samples of our local breast cancer patients in comparison to healthy control by using miRNA PCR Array.
Methods: In this study, plasma miRNA profiles from eight early-stage breast cancer patients and nine age-matched (± 2 years) healthy controls were characterized by miRNA array-based approach, followed by differential gene expression analysis, Independent T-test and construction of Receiver Operating Characteristic (ROC) curve to determine the capability of the assays to discriminate between breast cancer and the healthy control.
Results: Based on the 372-miRNAs microarray profiling, a set of 40 differential miRNAs was extracted regarding to the fold change value at 2 and above. We further sub grouped 40 miRNAs of breast cancer patients that were significantly expressed at 2-fold change and higher. In this set, we discovered that 24 miRNAs were significantly upregulated and 16 miRNAs were significantly downregulated in breast cancer patients, as compared to the miRNA expression of healthy subjects. ROC curve analysis revealed that seven miRNAs (miR-125b-5p, miR-142-3p, miR-145-5p, miR-193a-5p, miR-27b-3p, miR-22-5p and miR-423-5p) had area under curve (AUC) value > 0.7 (AUC p-value < 0.05). Overlapping findings from differential gene expression analysis, ROC analysis, and Independent T-Test resulted in three miRNAs (miR-27b-3p, miR-22-5p, miR-145-5p). Cohen's effect size for these three miRNAs was large with d value are more than 0.95.
Conclusion: miR-27b-3p, miR-22-5p, miR-145-5p could be potential biomarkers to distinguish breast cancer patients from healthy controls. A validation study for these three miRNAs in an external set of samples is ongoing.<br />.
Keywords: Biomarkers; HUSM; RT-PCR; breast cancer; miRNAs.
Figures
Similar articles
-
Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer.Cancer. 2018 Feb 15;124(4):785-796. doi: 10.1002/cncr.31062. Epub 2017 Nov 7. Cancer. 2018. PMID: 29112225 Free PMC article.
-
A two-miRNA signature of upregulated miR-185-5p and miR-362-5p as a blood biomarker for breast cancer.Pathol Res Pract. 2021 Jun;222:153458. doi: 10.1016/j.prp.2021.153458. Epub 2021 Apr 29. Pathol Res Pract. 2021. PMID: 33962174
-
Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis.Gene. 2018 Oct 5;673:181-193. doi: 10.1016/j.gene.2018.06.037. Epub 2018 Jun 18. Gene. 2018. PMID: 29913239
-
Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.Curr Probl Cancer. 2020 Aug;44(4):100540. doi: 10.1016/j.currproblcancer.2020.100540. Epub 2020 Jan 23. Curr Probl Cancer. 2020. PMID: 32007320 Review.
-
Systematic review of circulating MICRORNAS as biomarkers of cervical carcinogenesis.BMC Cancer. 2022 Aug 6;22(1):862. doi: 10.1186/s12885-022-09936-z. BMC Cancer. 2022. PMID: 35933332 Free PMC article.
Cited by
-
Role of miRNA‑145‑5p in cancer (Review).Oncol Rep. 2025 Mar;53(3):39. doi: 10.3892/or.2025.8872. Epub 2025 Jan 31. Oncol Rep. 2025. PMID: 39886965 Free PMC article. Review.
-
Unraveling Roles of miR-27b-3p as a Potential Biomarker for Breast Cancer in Malay Women via Bioinformatics Analysis.Int J Mol Cell Med. 2023;12(3):257-274. doi: 10.22088/IJMCM.BUMS.12.3.257. Int J Mol Cell Med. 2023. PMID: 38751652 Free PMC article.
-
Analysis of circulating extracellular vesicle derived microRNAs in breast cancer patients with obesity: a potential role for Let-7a.J Transl Med. 2023 Mar 31;21(1):232. doi: 10.1186/s12967-023-04075-w. J Transl Med. 2023. PMID: 37004031 Free PMC article.
-
Addressing the Clinical Feasibility of Adopting Circulating miRNA for Breast Cancer Detection, Monitoring and Management with Artificial Intelligence and Machine Learning Platforms.Int J Mol Sci. 2022 Dec 6;23(23):15382. doi: 10.3390/ijms232315382. Int J Mol Sci. 2022. PMID: 36499713 Free PMC article. Review.
-
Review of the Different Outcomes Produced by Genetic Knock Out of the Long Non-coding microRNA-host-gene MIR22HG versus Pharmacologic Antagonism of its Intragenic microRNA product miR-22-3p.Microrna. 2025;14(1):19-41. doi: 10.2174/0122115366282339240604042154. Microrna. 2025. PMID: 38952162 Review.
References
-
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
-
- Checka CM, Chun JE, Schnabel FR, et al. The relationship of mammographic density and age: implications for breast cancer screening. Am J of Roenigenol. 2012;198:292–5. - PubMed
-
- Cuk K, Zucknick M, Heil J, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2013;132:1602–12. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical